Login to Your Account



Pharma: Other News To Note


Thursday, November 8, 2012

• Sosei Group Corp., of Tokyo, and Novartis AG, of Basel, Switzerland, said an application has been submitted for the registration of QVA149, an investigational fixed-dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease in Japan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription